From Production Workshop to Clinical Ward: Key Bottlenecks and Collaborative Strategies in the Full-Chain Translation of Innovative Medicines

Zimin Song

doi:10.32629/jcmr.v7i3.5555

Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v7i3.5555

Zimin Song

China Medical University, Shenyang 110122, Liaoning, China

Abstract

Translation of innovative medicines from manufacturing workshop to clinical ward depends on stable quality, defensible clinical evidence, predictable regulation, and clinician adoption. This analysis identifies bottlenecks at process scale-up, clinical evidence generation, fragmented regulatory decisions, and data silos across stakeholders. It proposes collaborative strategies: joint CMC-clinical-access governance with shared decision rights, and adaptive evidence transfer through digital control points with green, amber, and red escalation triggers. A practical approach requires partners to share the same risk object, amendment triggers, and minimum evidence dataset, enabling faster translation while preserving evidentiary discipline throughout approval, supply, prescribing, reimbursement, and safety surveillance.

Keywords

innovative medicines; full-chain translation; CMC readiness

Full Text

PDF - Viewed/Downloaded: 0 Times

References

[1] Tan R, Hua H, Zhou S, Yang Z, Yang C, Huang G, et al. Current landscape of innovative medicine full-chain translation and regulatory support in China[J]. Signal Transduction and Targeted Therapy, 2025, 10: 220.
[2] Arlett P, Portier G, Sweeney F, Cooke E, Spiteri A, Enzmann H. A fast path from innovation to safe and effective innovative medicines in full-chain translation[J]. Clinical and Translational Science, 2025, 18(11): e70370.
[3] Wang T, Liu M, Peng B, Song X, Zhang C, Sun X, et al. From bench to bedside: clinical ward translation of innovative medicines in drug discovery and development[J]. BIO Integration, 2026, 6(1): 0198.
[4] Rizk M L, Ramamoorthy A, Stancil S L, Gorman A W, Johnson J A, Wagner J A, et al. The future of clinical translational pharmacology for full-chain translation of innovative medicine[J]. Clinical Pharmacology and Therapeutics, 2026, 120(1): 1-8.
[5] Vaudano E. The Innovative Health Initiative public-private partnership: collaborative strategy for full-chain translation of innovative medicine[J]. Frontiers in Medicine, 2025, 12: 1554948.
[6] Mao Z, Yan L. Artificial intelligence in drug discovery: production constraints and clinical ward translation of innovative medicines[J]. Frontiers in Pharmacology, 2026, 17: 1870527.

Citing this article:

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License